Table 2.
Evaluated outcomes in pairs of overlapping meta-analyses in 20 randomly selected topics
| Topic and PubMed ID | Outcomes evaluated |
|---|---|
| Open v endovascular aneurysm repair: | |
| 19836274 | Operative mortality; mortality related to abdominal aortic aneurysm; all cause mortality |
| 18658009 | Operative mortality* |
| Isometric handgrip exercise: | |
| 20009767 | Change in SBP; change in DBP |
| 21896934 | Change in SBP*; change in DBP*; anthropometrics; exercise tolerance; blood lipids; glucose |
| Dexamethasone in bacterial meningitis: | |
| 19475753 | Mortality*; hearing impairment or other neurological sequelae; adverse effects related to study regimens |
| 20138011 | Mortality; severe neurological sequelae; hearing loss |
| Peginterferon alpha-2a v alpha-2b in chronic hepatitis C: | |
| 20187106 | Sustained virologic response*; discontinuation for adverse events*; all cause mortality* |
| 20974315 | Sustained virologic response*; discontinuation for adverse events; all cause mortality |
| Pregabalin in fibromyalgia: | |
| 20418173 | Pain; fatigue; sleep; depressed mood; health related quality of life |
| 19588419† | Pain; adverse effects |
| Tocilizumab in rheumatoid arthritis: | |
| 21097801 | ACR50* |
| 20614469 | ACR50*; safety*; ACR70; ACR20; change in DAS28 score; proportion achieving good state; quality of life |
| Antibiotics for prevention of growth of abdominal aortic aneurysm: | |
| 20675312 | Growth rate* |
| 18365027 | Growth rate* |
| Timing of coronary angiography in NSTEACS: | |
| 20709722 | Death; MI; major bleeding; recurrent ischemia; repeat intervention; stroke; hospital stay length |
| 21872193 | Death; MI; major bleeding; recurrent ischemia; repeat intervention |
| Cyclophosphamide in interstitial lung disease: | |
| 20802426 | FVC improvement* |
| 18937831 | FVC improvement*; DLCO improvement* |
| Prophylactic antibiotics in laparoscopic cholecystectomy: | |
| 21154360 | Surgical site infection*; extra-abdominal infection* |
| 21443433 | Surgical site infection; extra-abdominal infection; major infection; all infections; positive bile cultures; length of hospital stay |
| Aspirin in diabetes: | |
| 21191260 | All cause mortality; cardiovascular mortality; major adverse cardiovascular events; MI; stroke; major bleeding events |
| 19897665 | All cause mortality, fatal or non-fatal MI or stroke; any bleeding; gastrointestinal symptoms; incidence of cancer |
| Shortened treatment duration of peginterferon and ribavirin in HCV1 patients with rapid virologic response: | |
| 19931204 | Sustained virologic response*; end of treatment virologic response; relapse rates |
| 21674553 | Sustained virologic response*; relapse rates; safety (treatment discontinuation) |
| Neuraxial anesthesia for lower limb revascularization: | |
| 20091615 | Death*; MI*; postoperative amputation*; pneumonia |
| 19488536 | Death*; MI*; postoperative amputation*; pneumonia |
| Cataract surgery for fall prevention: | |
| 20117700 | Vision improvement*; falls |
| 19370674 | Falls* |
| Statins for primary prevention in women: | |
| 18793814 | Death; cardiovascular events |
| 22300691 | Death; cardiovascular events |
| Statins for prevention of atrial fibrillation after cardiac surgery: | |
| 19698856 | Atrial fibrillation* |
| 19559266 | Atrial fibrillation* |
| Drug eluting stents for coronary chronic total occlusions: | |
| 20549695 | Restenosis; reocclusion; death; MI; TVR; TLR; stent thrombosis |
| 21419488 | MACE*; death; MI; TVR; TLR; TVF; restenosis; reocclusion; minimal lumen diameter; late lumen loss |
| Antibiotics in cirrhosis with upper gastrointestinal bleed: | |
| 10347104 | Infection; bacteremia and/or spontaneous bacterial peritonitis; spontaneous bacterial peritonitis; death |
| 21707680 | Death*; death from infection*; infection*; dropouts; rebleeding; length of hospitalization |
| Oral diflunisal for acute postoperative pain: | |
| 20393958 | At least 50% pain relief*; use of rescue medication; adverse events |
| 21901726 | At least 50% pain relief*; use of rescue medication; adverse events |
| Corticosteroids in septic shock: | |
| 19489712 | Death; shock reversal; superinfection |
| 15289273 | Death*; in hospital death; shock reversal; adverse events (gastroduodenal bleeding, superinfections, hyperglycemia, and other adverse effects) |
SBP=systolic blood pressure; DBP=diastolic blood pressure; ACR(x)=x% improvement according to American College of Rheumatology criteria; NSTEACS=non-ST elevation acute coronary syndrome; DAS28=disease activity score; MI=myocardial infarction; FVC=forced vital capacity; DLCO=diffusing capacity for carbon monoxide; MACE=major adverse cardiac events; TVR=target vessel revascularization; TLR=target lesion revascularization; TVF=target vessel failure.
*Primary or unique outcome.
†Acute and chronic pain including fibromyalgia.